05-May-2015 - Expedeon AG

SYGNIS signs non-exclusive distribution agreement with Cambridge Bioscience Ltd. for UK and Ireland

SYGNIS AG announced a distribution agreement with Cambridge Bioscience for the commercialization of SYGNIS’ proprietary product portfolio in the UK and Ireland.

Under the terms of the agreement, Cambridge Bioscience will promote, market, sell and support TruePrime™ products for primer-free WGA as well as SunScript™ thermostable reverse transcriptase kits for the translation of RNA into DNA to researchers in molecular biology in the UK and Ireland.

Cambridge Bioscience is a UK based distributor of cutting-edge life science research products including a broad portfolio of innovative products and technologies for molecular biology applications such as NGS, epigenetics, gene regulation, cloning, DNA extraction and purification, amplification, quantification, delivery as well as high-end instrumentation.

Facts, background information, dossiers
  • SYGNIS Pharma
  • Cambridge Bioscience
More about Expedeon
  • News

    SYGNIS AG signs supply agreement with US Biological

    SYGNIS AG announced it has signed a supply agreement with US Biological for its Innova Lightning-Link technology. Heikki Lanckriet, CEO and CSO of SYGNIS AG, commented: “We are delighted that US Biological has chosen Lighting-Link as its preferred method for antibody labelling. The technol ... more